German orthopedic implant maker Syntellix said today that it’s planning an initial public offering on the Singapore Stock Exchange and named a new CFO. Syntellix makes screws and pins from a magnesium-based material it developed, called Magnezix, that’s designed to be resorbed and converted into bone over time. Its products are approved in Mexico, Vietnam […]
Vericel inks licensing deal for MediWound’s NexoBrid, posts Q1 earnings
Vericel (NSDQ:VCEL) said yesterday it inked an exclusive U.S. licensing and supply agreement with MediWound (NSDQ:MDWD) for its NexoBrid biological product, and reported first quarter earnings that missed expectations on Wall Street. The NexoBrid is a topically-administered product intended to enzymatically remove nonviable burn tissue in patients with deep partial and full-thickness thermal burns. The product has […]
Misonix puts up $97m in stock for Solsys Medical
Misonix (NSDQ:MSON) said yesterday that it put $97 million in stock on the table for Solsys Medical, formerly Soluble Systems, and its TheraSkin regenerative wound dressing. The deal calls for Farmingdale, N.Y.-based Misonix to issue 5.7 million new shares to Solsys stockholders, which would leave MSON investors owning 64% of the new company and former Solsys […]
Smith & Nephew closes Osiris Therapeutics, Leaf Healthcare buys
Smith & Nephew (NYSE:SNN) said today that it closed both its $660 million acquisition of Osiris Therapeutics (NSDQ:OSIR) and its purchase of Leaf Healthcare and its Leaf Patient Monitoring System. The London-based company said that it paid $19 per share in cash for Osiris, which develops and produces regenerative medicine products including skin, bone grafts and articular […]
TissueTech raises $55m
TissueTech has raised approximately $55.3 million in a new round of equity financing, according to a recently posed SEC filing. The Doral, Fla.-based company makes amniotic membrane- and umbilical cord-based products designed to treat ocular surface diseases (its Bio-Tissue subsidiary) and musculoskeletal conditions and wound care (its Amniox Medical business). Money in the round came […]
Admedus deals vaccines biz to Constellation Therapeutics
Admedus (ASX:AHZ) said today that it agreed to sell its vaccines business to Constellation Therapeutics in a deal that will see it own nearly 30% of the Chinese company. Other shareholders in the vaccines would own another 11%, Queensland, Australia-based Admedus said. Sun Bright Holdings will own the remainder and put in $18 million until November […]
Prellis Biologics raises $9m
Prellis Biologics has raised $8.7 million in a new round of equity financing, according to a recently posed SEC filing. The San Francisco-based company is developing ultra-fast high-resolution holographic laser printing technology intended for use in creating human organs and tissues, according to its website. Prellis Biologics offers a number of products based around vascularized […]
Osiris shareholders sue to block $660m merger with Smith & Nephew
A group of Osiris Therapeutics (NSDQ:OSIR) shareholders is suing to block its $660 million acquisition by Smith & Nephew (NYSE:SNN) because the purchase price is too low. Earlier this month the British orthopedics and wound care giant put $19 per share on the table to acquire Osiris and its regenerative medicine portfolio, representing a 37% premium on the 90-day […]
PolarityTE reveals SEC investigation
PolarityTE (NSDQ:PTE) this week revealed that it is the target of an SEC investigation into possible violations of federal securities laws. The Salt Lake City, Utah-based company said that it received a copy of a formal order of investigation from the SEC on March 4, exploring possible violations of fraud and price manipulations, according to an […]
Admedus wins CE Mark for CardioCel 3D, VascuCel products
Admedus (ASX:AHZ) has won CE Mark approval in the European Union for its CardioCel 3D and VascuCel products which use its proprietary Adapt tissue technology, according to a report from ProactiveInvestors. The Australian company plans to begin the first stage of a commercial launch of the devices in the region later this month, according to the […]
Smith & Nephew puts up $660m for Osiris Therapeutics
Smith & Nephew (NYSE:SNN) said today that it agreed to put $660 million on the table to acquire Osiris Therapeutics (NSDQ:OSIR) and its regenerative medicine portfolio. The British orthopedics and wound care giant said the $19-per-share deal is a 37% premium on the 90-day volume-weighted average for OSIR shares. It’s structured as a two-step tender […]
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 52
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube